Binimetinib 15 MG

DRUG3 trials

Sponsors

Intergroupe Francophone de Cancerologie Thoracique, Pierre Fabre Medicament, National Cancer Center, Japan

Conditions

BRAF V600 MutationBRAF V600ELow-grade GliomaMelanomaMetastatic MelanomaNon Small Cell Lung CancerPancreatic CancerUnresectable Melanoma

Phase 1

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

CompletedNCT05810740

Pierre Fabre MedicamentBRAF V600 Mutation, Melanoma, Metastatic Melanoma +1

Start: 2022-08-31End: 2023-01-18Updated: 2024-09-19

Phase 2

ENCOrafenib With Binimetinib in bRAF NSCLC

Active, not recruitingNCT04526782

Intergroupe Francophone de Cancerologie ThoraciqueBRAF V600E, Non Small Cell Lung Cancer

Start: 2021-01-19End: 2027-03-01Target: 119Updated: 2026-08-11

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

RecruitingNCT06159478

National Cancer Center, JapanLow-grade Glioma, Pancreatic Cancer

Start: 2023-03-29End: 2027-09-30Target: 32Updated: 2023-12-13

Related Papers

Perfume trial: Phase II trial of binimetinib in patients with <i>BRAF</i> fusion-positive low-grade glioma or pancreatic cancer.

Journal of Clinical Oncology2025-05-28